Cargando…
A randomized, double‐blind, placebo‐controlled, dose‐finding trial with Lolium perenne peptide immunotherapy
BACKGROUND: A novel subcutaneous allergen immunotherapy formulation (gpASIT+™) containing Lolium perenne peptides (LPP) and having a short up‐dosing phase has been developed to treat grass pollen–induced seasonal allergic rhinoconjunctivitis. We investigated peptide immunotherapy containing the hydr...
Autores principales: | Mösges, R., Kasche, E. M., Raskopf, E., Singh, J., Sohlich, L., Astvatsatourov, A., Shah‐Hosseini, K., Pirotton, S., Haazen, L., Durham, S. R., Legon, T., Zadoyan, G., Shamji, M. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947135/ https://www.ncbi.nlm.nih.gov/pubmed/29150857 http://dx.doi.org/10.1111/all.13358 |
Ejemplares similares
-
Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B‐cell response in seasonal allergic rhinitis patients
por: Mösges, R., et al.
Publicado: (2018) -
Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double‐blind, placebo‐controlled trial
por: Mösges, R., et al.
Publicado: (2018) -
Vernalization Mediated Changes in the Lolium perenne Transcriptome
por: Paina, Cristiana, et al.
Publicado: (2014) -
Genomic prediction of crown rust resistance in Lolium perenne
por: Arojju, Sai Krishna, et al.
Publicado: (2018) -
Karyotype reshufflings of Festuca pratensis × Lolium perenne hybrids
por: Majka, Joanna, et al.
Publicado: (2017)